Regen Chem

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing breakthrough treatments for peripheral neuropathies and other chronic conditions. The company's primary focus is on the development of highly selective histone deacetylase 6 (HDAC6) inhibitors, which aim to restore nerve function and alleviate pain without the dose-limiting toxicities associated with non-selective HDAC inhibitors. Their lead candidate, ricolinostat, is being evaluated for its potential to treat diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. By targeting the underlying biological mechanisms of nerve damage, Regenacy seeks to provide disease-modifying therapies for patients with limited treatment options.